Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
AssigneeGlaxo Group Limited
InventorsMichael Simon Anson, Caroline Jane Day, Jonathan Paul Graham, Leanda Jane Kindon, Grahame Robert Woollam
Life of this patent
Estimating the term…
Abstract
The invention relates to the compound (2S)-2-amino-2-{5-[4-(octyloxy)-3-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-1-propanol hemi-fumarate, processes for its preparation, pharmaceutical compositions containing them and its use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.
Claims9
(2S)-2-amino-2-{5-[4-(octyloxy)-3-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-1-propanol hemi-fumarate.
5-7. (canceled)
A method of treating a condition or disorder mediated by a S1P1 receptor in a mammal, including a human, in need thereof, comprising:
- administering to the mammal a therapeutically effective amount of (2S)-2-amino-2-{5-[4-(octyloxy)-3-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-1-propanol or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.